Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epigenomics and AstraZeneca form pact:

This article was originally published in Clinica

Executive Summary

Bolstering its efforts in the field of personalised medicine, Epigenomics has teamed up with AstraZeneca to discover biomarkers that may form part of AstraZeneca's strategy for targeting drugs at the patients most likely to respond to them. Berlin, Germany-based Epigenomics will use its proprietary technology to identify DNA methylation markers from clinical tumour samples embedded in paraffin for use in AstraZeneca's cancer drug discovery and development programme. The programme will initially focus on AstraZeneca's selective epidermal growth factor receptor tyrosine kinase inhibitor, Iressa.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel